News AstraZeneca sells rights to cholesterol drug Crestor to Grun... AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
